Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry

All authors were involved in the maintenance of the Connect (R) MDS/AML Disease Registry. All authors directed the development, critically reviewed, and approved the submitted version of this manuscript and are fully responsible for all content and editorial decisions. Celgene Corporation supported the authors in collecting and analyzing the data reported in this Registry. The Connect (R) MDS/AML Disease Registry is sponsored and funded by Celgene Corporation. The authors would like to thank all the patients and their families, nurses, study personnel and investigators who participated in the Connect (R) MDS/AML Disease Registry. The Connect (R) MDS/AML Disease Registry Scientific Steering Committee acknowledges the contributions of all past and current members of the committee for their guidance in the design of the Registry and participation in the analysis of the data, including Mehrdad Abedi, Rafael Bejar, Christopher Cogle, Harry Erba, Kathryn Foucar, Guillermo Garcia-Manero, Tracy George, David Grinblatt, Rami Komrokji, Sandra Kurtin, Jarek Maciejewski, Daniel Pollyea, Dennis Revicki, Gail Roboz, Michael Savona, Bart Scott, Mikkael Sekeres, David Steensma, and Michael Thompson. Yun Li and Kevin Deng provided statistical support. The authors received writing and editorial support in the preparation of this manuscript from Lynne Cairns, PhD, of Excerpta Medica, funded by Bristol-Myers Squibb.